{
    "title": "Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits -report",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10472717/Price-COVID-treatments-Pfizer-Merck-GSK-align-patient-benefits-report.html",
    "date": "2022-02-03",
    "keywords": [
        "risk",
        "course",
        "icer",
        "covid19",
        "report",
        "paxlovid",
        "sotrovimab",
        "antibody",
        "hospitalization",
        "cost",
        "beasley",
        "illness",
        "draft",
        "merck",
        "emergency",
        "government",
        "molnupiravir",
        "omicron",
        "variant",
        "highrisk",
        "pearson",
        "fluvoxamine",
        "year",
        "value",
        "qaly",
        "analysis",
        "research",
        "organization",
        "institute",
        "review",
        "incs",
        "amp",
        "cos",
        "drug",
        "glaxosmithkline",
        "plc",
        "vir",
        "biotechnology",
        "basis",
        "freeofcharge",
        "lone",
        "treatment",
        "virus",
        "cut",
        "reduction",
        "alignment",
        "price",
        "president",
        "pfizer",
        "home",
        "hospital",
        "infusion",
        "costeffectiveness",
        "generic",
        "pill",
        "disorder",
        "depression",
        "university",
        "minnesota",
        "december",
        "authorization",
        "covid",
        "antidepressant",
        "antiinflammatory",
        "formula",
        "life",
        "health",
        "patient",
        "pandemic",
        "infection",
        "effectiveness",
        "comment",
        "evidence",
        "march",
        "reporting",
        "deena",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}